Lotus Eye Hospital Institute Ltd vs Transgene Biotek Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Lotus Eye Hospital & Institute Ltd is ₹ 112.75 as of 23 Oct 15:30 . The P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 25.38 crore on March 2025 . This represents a CAGR of -6.06% over 5 years The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013. Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy. Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.

About Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

FAQs for the comparison of Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd

Which company has a larger market capitalization, Lotus Eye Hospital & Institute Ltd or Transgene Biotek Ltd?

Market cap of Lotus Eye Hospital & Institute Ltd is 234 Cr while Market cap of Transgene Biotek Ltd is 19 Cr

What are the key factors driving the stock performance of Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd?

The stock performance of Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd?

As of October 25, 2026, the Lotus Eye Hospital & Institute Ltd stock price is INR ₹112.75. On the other hand, Transgene Biotek Ltd stock price is INR ₹2.57.

How do dividend payouts of Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd compare?

To compare the dividend payouts of Lotus Eye Hospital & Institute Ltd and Transgene Biotek Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.